Enovis Corporation
NYSE:ENOVMedical - Devices
+$0.73 today
- Market cap
- $1.56B
- Beta
- 1.49
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$20.02
Volume 0.88M
Average 0.99M
ENOV Pre-Tax Margin
Income before tax as a percentage of revenue.
Enovis CorporationNYSE: ENOV
Pre-Tax Margin · Q1 FY2026 · quarter ended Apr 2026
Pre-tax margin widens to 0.1%
Pre-tax margin was 0.1% in Q1 FY2026, up 10.4 pp from a year earlier. On a trailing-twelve-month basis it was -48.3%, down 11.1 pp year over year. Over 3 fiscal years it narrowed by 51.4 pp.
Context
- Pre-tax margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -51.6%
- Year-over-year change
- -12.5pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -51.6% | -12.5pp |
| FY2024 | 2024-12-31 | -39.0% | -35.1pp |
| FY2023 | 2023-12-31 | -3.9% | -3.8pp |
| FY2022 | 2022-12-31 | -0.1% | +8.4pp |
| FY2021 | 2021-12-31 | -8.5% | — |
Pre-Tax Margin vs competitors
How ENOV compares with its peers on the latest reported figures
- ENOV's LTM Apr 2026 pre-tax margin of -48.3% is the lowest of the 16 companies compared; the peer median is 11.7%.
- Its year-over-year change of -11.1 pp is the 15th highest of 16, against a peer median of -0.6 pp.
- Over three fiscal years its change of -51.4 pp compares with a peer median of +1.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 19.0% | +1.4 pp | +2.7 pp | |
| LTM Jun 2026 | 19.0% | +1.0 pp | -5.3 pp | |
| LTM Feb 2026 | 18.0% | -0.6 pp | +15.4 pp | |
| LTM Mar 2026 | 17.6% | -5.1 pp | -5.1 pp | |
| LTM Jul 2026 | 15.1% | +1.7 pp | +1.4 pp | |
| LTM Jul 2026 | 13.6% | -0.6 pp | -4.7 pp | |
| LTM Jul 2026 | 12.8% | -5.0 pp | +1.1 pp | |
| LTM Sep 2026 | 11.7% | +2.8 pp | -2.4 pp | |
| LTM Jun 2026 | 11.5% | +1.8 pp | +7.5 pp | |
| LTM Jul 2026 | 10.3% | +4.5 pp | -6.3 pp | |
| LTM Mar 2026 | 5.7% | -1.6 pp | +5.4 pp | |
| LTM Mar 2026 | 5.5% | -2.1 pp | -3.9 pp | |
| LTM Jun 2026 | 4.6% | -5.7 pp | +2.5 pp | |
| LTM Apr 2026 | -6.0% | -0.8 pp | -11.6 pp | |
| LTM Jul 2026 | -7.0% | -21.6 pp | +1.1 pp | |
| LTM Apr 2026 | -48.3% | -11.1 pp | -51.4 pp | |
| Peer median (excluding ENOV) | 11.7% | -0.6 pp | +1.1 pp | |
Competitors are the stored peer set for ENOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.43B | 1.56B | 1.71B | 2.11B | 2.25B |
| Cost of Revenue | 648.51M | 693.72M | 716.42M | 926.87M | 902.79M |
| Gross Profit | 777.68M | 869.38M | 990.78M | 1.18B | 1.35B |
| Gross Margin | 54.5% | 55.6% | 58.0% | 56.0% | 59.8% |
| Research & Development | 49.09M | 60.83M | 75.33M | 91.3M | 120.33M |
| Selling, General & Admin | 665.78M | 772.91M | 830.31M | 939.36M | 1.07B |
| Operating Expenses | 840.47M | 940.56M | 1.06B | 1.96B | 1.36B |
| Depreciation & Amortization | 262.92M | 219.71M | 217.11M | 284.8M | 294.38M |
| EBITDA | 170.25M | 241.69M | 169.73M | (481.03M) | (830.22M) |
| EBITDA Margin | 11.9% | 15.5% | 9.9% | -22.8% | -36.9% |
| Operating Income | (62.8M) | (71.18M) | (65.71M) | (775.72M) | (18.87M) |
| Operating Margin | -4.4% | -4.6% | -3.8% | -36.8% | -0.8% |
| Interest Income | 0 | 200K | 0 | 0 | 0 |
| Interest Expense | 29.11M | 24.95M | 19.75M | 57.1M | 34.82M |
| Other Income / Expenses | (58.98M) | 69.11M | (1.42M) | (47.21M) | (1.14B) |
| Income Before Tax | (121.78M) | (2.07M) | (67.13M) | (822.92M) | (1.16B) |
| Pre-Tax Margin | -8.5% | -0.1% | -3.9% | -39.0% | -51.6% |
| Income Tax Expense | (19.53M) | 36.12M | (13.29M) | 4.49M | 22.29M |
| Net Income | 71.66M | (13.29M) | (33.26M) | (825.49M) | (1.18B) |
| Net Margin | 5.0% | -0.9% | -1.9% | -39.2% | -52.7% |
| EPS (Basic) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| EPS (Diluted) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| Weighted Avg Shares | 51.14M | 54.07M | 54.53M | 55.28M | 56.79M |
| Weighted Avg Shares (Diluted) | 51.14M | 54.07M | 54.49M | 55.28M | 56.79M |
Enovis Corporation
NYSE:ENOV
Intrinsic Alpha fair value
Locked
Current Price
$27.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.